FOSL2 and neoplasm: Previous studies have reported that FOSL2 can indirectly promote angiogenesis in tumor tissues, even when classical VEGF signaling is inhibited by anti-VEGF antibodies or axitinib.36 These findings suggest that FOSL2 may be adaptively upregulated in response to antiangiogenic therapies such as lenvatinib and sorafenib.